Cancer Drug Development Using Glucose Metabolism Radiopharmaceuticals

Title: Cancer Drug Development Using Glucose Metabolism Radiopharmaceuticals

Volume: 15 Issue: 9

Author(s): Y. Y. Sun and Y. Chen

Affiliation:

Keywords: 18F-FDG, positron emission tomography, SPECT, imaging, radiopharmaceutical, 9mTc, 188Re

Abstract: Imaging of glucose metabolism has resulted in significant improvements in staging and follow-up in oncology. 18F-FDG PET has become a routine clinical test for most solid tumours. Several radionuclide-labeled derivatives of deoxyglucose that have shown that glucose metabolic imaging may be a useful tool for improving tumour staging, restaging, and monitoring of tumour response to therapy.

Cite this article as:

Sun Y. Y. and Chen Y., Cancer Drug Development Using Glucose Metabolism Radiopharmaceuticals, Current Pharmaceutical Design 2009; 15 (9) . https://dx.doi.org/10.2174/138161209787582048